Close

Needham & Company Starts Acer Therapeutics (ACER) at Buy

December 20, 2018 6:23 AM EST Send to a Friend
Needham & Company analyst Serge Belanger initiates coverage on Acer Therapeutics (NASDAQ: ACER) with a Buy rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login